Sage Journals: Discover world-class research

Abstract

Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease that involves host genetics, the microbiome, and inflammatory responses. The current consensus is that the disruption of the intestinal mucosal barrier is the core pathogenesis of IBD, including intestinal microbial factors, abnormal immune responses, and impaired intestinal mucosal barrier. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) are dominant mediators in maintaining the homeostasis of the intestinal mucosal barrier, which play critical roles in sensing the commensal microbiota, maintaining homeostasis, and regulating intestinal inflammation. Blocking NLRs inflammasome activation by botanicals may be a promising way to prevent IBD progression. In this review, we systematically introduce the multiple roles of NLRs in regulating intestinal mucosal barrier homeostasis and focus on summarizing the activities and potential mechanisms of natural products against IBD. Aiming to propose new directions on the pathogenesis and precise treatment of IBD

Keywords

IBD intestinal mucosal barrier natural products NLRs pathogenesis

Introduction

Inflammatory bowel disease (IBD) is an illness with an unknown etiology and pathogenesis characterized by chronic inflammation of the intestinal mucosa with recurrent and persistently delayed episodes, encompassing ulcerative colitis (UC) and Crohn’s disease (CD). IBD patients are mainly dispersed in developed countries (>0.3%), but the incidence of IBD in newly industrialized countries is rapidly growing (the annual growth rate percentage has reached 14.9%).¹ IBD has thus evolved into a global disease, and the number of IBD patients is expected to reach 30 million by the year 2025.² The number of IBD patients is increasing year by year, and there is an urgent need to explore the pathogenesis of IBD and find potential targets and drugs for the treatment of IBD.

IBD is known to be caused by interactions between genetics, host immunity, the mucosal barrier, and the gut microbiome, but its exact etiology remains unclear.³ Impaired mucosal barrier function is considered to be the primary pathogenic factor in the development of IBD.^4,5 As the primary defense barrier of the body, the intestinal mucosal barrier has made outstanding contributions to regulating and maintaining the homeostasis of the internal environment.⁶ Once the intestinal mucosal barrier function is disrupted by various factors, the immune balance is disrupted, triggering an inflammatory response that is ultimately involved in the development of IBD.⁷ It is believed that NOD-like receptors (NLRs) are the main mediators in maintaining intestinal mucosal barrier homeostasis,^8,9 including regulation of intestinal microbiota, inflammatory response, cellular senescence, and cell death.¹⁰ In particular, the role of NLRs in modulating the intestinal mucosal barrier and immune mechanisms has become a hot topic of research and is considered a valuable therapeutic target for the treatment of IBD.

It is thought that aberrant activation of NLRs is the main cause of intestinal mucosal barrier dysfunction. Blocking NLR-inflammasome activation by botanicals or synthetic small molecules may be a valuable way to prevent IBD progression. Natural bioactive compounds are an important resource for drug discovery and modification. Several studies suggest that natural products (NPs), including dietary, and herbal formulations or their extracts, have unique efficacy in the health management of chronic inflammatory diseases.^11,12 In this review, we elucidate the composition and function of the intestinal mucosal barrier and discuss the potential role of NLRs in regulating the intestinal mucosal barrier and inflammatory mechanisms. We also summarize the original extracts and traditional medicines targeting NLRs against IBD with the potential to develop NPs.

Literature search strategy

Studies were identified by searching electronic medical databases: Web of Science, PubMed, SciFinder, OvidSP, Scopus, MEDLINE, ScienceDirect, IMBIOMED, and Cochrane database, from January 1983 to February 2023. All human and animal studies are included to evaluate the role of NOD-like receptors in the pathogenesis of IBD, ensuring attention to the latest and comprehensive literature. MeSH terms and/or text words included the broad terms NOD-like Receptors, inflammatory bowel disease, intestinal mucus barrier, and Botanicals. We also searched specific pathogens including NLRP1, NOD2, NLRP3, NLRP6, NLRC4, NOD1, NLRP12, biological barrier, gut microbiota, chemical barrier, mechanical barrier, immunological barrier, botanicals, natural products, flavonoids, terpenoids, plant extracts, alkaloids, phenylpropanoids, treatment, therapeutic, pathogenesis, epidemiology, combined with ‘AND inflammatory bowel disease OR UC OR Crohn disease OR colitis’. We also reviewed the references of relevant IBD disease review articles and studies that met the inclusion criteria of other relevant articles.

The composition and function of the intestinal mucosal barrier

Biological barrier

The gut microbiome is mainly composed of bacteria, archaea, fungi, viruses, and bacteriophages.¹³ The gut microbiota is dominated by bacteria, especially members of the phylum Bacteroidetes, Firmicutes, Actinobacteria, and Proteobacteria, the sum of which exceeds 90%.¹⁴ The gut microbiota plays an important role in several aspects of host homeostasis. The gut microbiota plays an important role in several aspects of host homeostasis: (1) Aid the host digest and metabolize indigestible nutrients such as xylan, cellulose, and resistant starch. (2) Provide substrates, enzymes, and energy for host metabolic processes. (3) Prevent the invasion of harmful bacteria by secreting bacterial toxins, producing short-chain fatty acids, promoting intestinal peristalsis, occupying the adhesion sites of pathogenic bacteria, and competing for nutrients. (4) Suppresses the gut immune system’s hyperreactive immune response to antigens to maintain immune tolerance and homeostasis.

Chemical barrier

The intestinal chemical barrier consists of mucus secreted by intestinal epithelial cells, digestive juice fluids (gastric acid, bile), and antimicrobial peptides (AMPs), which cooperate to form a complex protective mechanism.¹⁵ The role of mucus is to insulate intestinal bacteria from contact with the intestinal epithelium, thereby avoiding tissue damage and microbiota translocation.¹⁶ Stomach acid and bile acid could inhibit the growth and reproduction of bacteria, thus protecting the intestinal tract from pathogenic bacteria infection.¹⁷ AMPs can have multiple effects on intestinal mucosal homeostasis; in addition to killing ingested pathogens, controlling the composition of the gut microbiota can also coordinate adaptive immune responses.¹⁸ The intestinal chemical barrier is a good support for the intestinal microbial barrier and plays an important role in maintaining the intestinal microecological balance.

Mechanical barrier

The intestinal mucosal mechanical barrier is composed of intestinal mucosal epithelial cells, the apical junction complex (AJC), and the lamina propria. The AJC is located at the apical junction between adjacent intestinal epithelial cells and is composed of adherens junctions (AJs) and tight junctions (TJs).¹⁹ AJs and TJs include two cell-cell adhesion modes with different functions. The adhesion junction contains intracellular components such as α-catenin, β-catenin, and p120-catenin, as well as the transmembrane protein E-cadherin, which triggers and regulates contact between cells in addition to regulating maturation.²⁰ TJs are composed of claudin, the transmembrane proteins occludin, and the cytoplasmic scaffolding proteins ZO-1, -2, and -3, which, together, regulate the paracellular pathways of ion and solute movement between cells.²¹ Mechanical barriers have several critical physiological functions: (1) Preventing harmful entities in the lumen from invading the body, including foreign antigens, microorganisms, and toxins. (2) Selectively allowing essential dietary nutrients, electrolytes, and water to enter the circulation through the intestinal cavity. (3) Secretion of mucus, antimicrobial proteins (AMPs), and immunoglobulin A (SIgA), which provides the basis for the intestinal chemical barrier, immune barrier, and other barrier functions.

Immunological barrier

The intestinal mucosal immune barrier is mainly composed of gut-associated lymphocyte tissue (GALT) and diffuse immune cells [innate immune cells (neutrophils, monocyte/macrophages, dendritic cells, mast cells, and innate lymphoid cells) and adaptive immune cells (B and T cells)].²² Moreover, epithelial cells are increasingly viewed as an integral part of the immune barrier.²³ The GALT secretes immunoglobulin A (IgA) antibodies, and IgA forms IgA – antigen complexes with antigenic substances. The IgA antigen complexes bind to the receptors on M cells. The antigens are then transferred to the lamina propria and subsequently presented to dendritic cells.²⁴ Antigen-presenting cells in the lamina propria receive immune-stimulating antigens from the cavity, process those antigens, and present them to T cells. The IL-12 secreted by antigen-presenting cells can promote the production of Th1 by T cells, but the simultaneous production of IL-10 limits Th1 immune responses.²⁵ Additionally, IgA promotes the renewal of intestinal epithelial cells, and repairs damage over time, stabilizing the intestinal mucosal barrier.²⁶ In summary, the main function of the intestinal mucosal immune barrier is to recognize antigens in the body, generate humoral and cellular immunity, and effectively remove antigens.

In conclusion, the intestinal mucosal barrier is an important protective mechanism and defense system for maintaining body health. Moreover, it is worth mentioning that the interaction between each barrier forms a complex regulatory network, which fully plays the role of preventing the invasion of pathogenic microorganisms, regulating antigen import, and inhibiting inflammation (Figure 1).

Figure 1.

Components of the intestinal mucosal barrier.

NLRs family and signaling mechanisms in the intestinal epithelial barrier

NLRs are composed of multiple domains, including a C-terminal domain, a series of leucine-rich repeats (LRRs), a central nucleotide-binding NACHT domain, and a variable N-terminal effector domain. Specifically, NLRs are divided into five subfamilies based on their unique N-terminal effecter domains: NLRAs with unique acidic activation domains, NLRBs feature a baculovirus inhibitor of apoptosis repeat (BIR)-like domain, NLRCs that have a caspase activation and Death domain or a recruitment domain (CARD), and the NOD and leucine-rich-repeat-containing protein (NLRP) subfamily NLRAs embody a PYRIN domain.²⁷ The NOD and leucine-rich-repeat-containing protein X (NLRX) subfamily contains only one member, which has an undefined N-terminal domain and has no significant homology with the N-terminal domain of other NLR subfamily members. The LRR domains are responsible for recognizing molecular patterns, including the corresponding components of PAMPs/DAMPs. The characteristic NACHT domain has dNTPase activity and mainly regulates ATP-dependent oligomerization. The N-terminal effector domain is the most prominent component of the NLRs and binds to various linker molecules and downstream effectors to mediate signal transduction.

NLRs are widely expressed in the gut, and their role in the pathogenesis of IBD was previously demonstrated (Table 1).^28,29 NOD1 and NOD2 are involved in the recognition of infectious bacteria, induction of immune responses, and protection of the intestinal mucosal barrier from bacterial erosion through the activation of nuclear factor kappa B (NF-κB).^30,31 The NLRP3 and NLRC4 assemblages respond to some microorganisms or parasites by activating caspase-1, producing IL-1β and IL-18, and initiating inflammatory processes. NLRP6 recognizes Listeria monocytogenes and recruits caspases, and Gasdermin D (GSDMD) cleavage further enhances NLR’s role as an important molecule in cell death.³² Similarly, NLRP12 was demonstrated to be crucial in the regulation of interferon and cytokine production, as well as the maintenance of immune homeostasis.³³ Moreover, cell death mediated by NLR-inflammasome activation protects host cells from attack by pathogens, by impeding the nutrient supply to the pathogens,³⁴ and the activated bystander cells can also secrete antimicrobial agents that arrest pathogen expansion and disease aggravation.³⁵ However, the specific molecular basis of the causal relationship between NLRs and IBD remains enigmatic. Nonetheless, due to the central roles of NLRs in immune regulatory signaling, they are considered as potential therapeutic targets for IBD.

Table 1.

NLRs in IBD.

Subfamily	NLR	Cells	Effect	References
NLRC	NOD1	Intestinal epithelial cells and dendritic cells	Protection	Chen et al.³⁶ Le Bourhis et al.³⁷
	NOD2	Intraepithelial lymphocyte cells (IELs), enterocytes, Paneth cells, and goblet cells	Protection	Al Nabhani et al.³⁸ Jiang et al.³⁹ Richardson et al.⁴⁰ Shanahan et al.⁴¹
	NOD2	/	Aggravation	Corridoni et al.⁴²
	NLRC4	Intestinal epithelial cells and phagocytes	Protection	Sellin et al.⁴³ Franchi et al.⁴⁴
	NLRC4	/	Aggravation	Steiner et al.⁴⁵
NLRP	NLRP1	Intestinal epithelial cells	Protection	Williams et al.⁴⁶
	NLRP1	Macrophages	Aggravation	Wang et al.⁴⁷
	NLRP3	Macrophages and neutrophils	Aggravation	Ranson et al.⁴⁸ Chen et al.⁴⁹
	NLRP3	Macrophages and neutrophils	Protection	Yao et al.⁵⁰
	NLRP6	Intestinal epithelial cells	Protection	Kempster et al.⁵¹ Yin et al.⁵²
	NLRP12	Macrophages and dendritic cells	Protection	Chen et al.⁵³
LRR PYD NACHT FIIND CARD

IBD, inflammatory bowel disease.

NOD-like receptors regulate homeostatic intestinal epithelial barrier function

Role of NLRs in modulating intestinal biologic barriers

The gut microbiota is equivalent to a ‘hidden organ’ that helps maintain a healthy mucosal barrier. The composition and diversity of the intestinal microbiota are influenced by host genes.^54,55 To assess the contribution of NLRs to the intestinal microbiota in IBD, Elinav et al. analyzed the fecal microbiota based on 16S rRNA. The results showed that the frequency of Prevotella in NLRP6−/− mice were higher. Compared to wild-type mice, NLRP6-/- mice exhibit a higher susceptibility to colitis.⁵⁶ Similarly, the study of Seregin et al. demonstrated that NLRP6 could alter Akkermansia muciniphila colonization, preventing IBD, in IL10−/− mice.⁵⁷ Interestingly, NLRP6−/− mice are resistant to systemic Escherichia coli, Salmonella typhimurium, and Listeria monocytogenes infections.⁵⁸ Gut mucosal microbiome dysbiosis was also reported in mice deficient in NLRP3. Hirota et al. reported that NLRP3−/− mice exhibited enhanced susceptibility to colitis and lower levels of B-defensins compared to wild-type mice, most likely due to altered gut microbiota compositions. Notably, the levels of potentially pathogenic bacteria increased; for example, Enterobacteriaceae, Genus mycobacterium, Collinsella, Subdoligranulum, Clostridium, and Ralstonia increased significantly.⁵⁹ However, recent studies contradicted these observations by showing that NLRP3−/− mice were resistant to colitis.⁶⁰ Further research showed that mice lacking the NLR components NLRP3, NLRC4, and caspase-1 were highly sensitive to Citrobacter. rodentium-induced gastrointestinal inflammation and could not control C. rodentium due to defects in the generation of IL-18 and IL-1β.⁶¹ Moreover, NLRP3-mutated mice showed reshaping of the gut microbiota and the appearance of regional regulatory T cells (Tregs) to maintain homeostasis and compensate for otherwise-harmful intestinal inflammation.⁴⁴ The NLRP3 inflammasome plays a significant role in the pathogenesis of colitis, although NLRP3 was found to have both protective and disadvantageous functions in studies on mucosal immunity. Different results are associated, for example, with the mouse/human genetic backgrounds,⁶² according to the composition of the gut microbiota,⁶³ with different colitis models,⁶⁴ or according to the method of inducing colitis (the concentration of DSS, the continuance of DSS delivery, and the number of cycles).

In addition, the regulation of the microbiota of the ileum and the bactericidal activity of ileal crypts are largely determined by NOD2, mainly by altering the interaction between mucosal immunity and ileal microbiota. Biswas et al. reported that NOD2−/− mice presented increased loads of commensal bacteria and pathogens at the terminal ileum. Further analysis showed that NOD2−/− mice experienced a remarkable increase in the amount of Bacteroides, Firmicutes, and Bacillus in the terminal ileum compared to wild-type littermate controls.⁶⁵ Notably, increased intestinal inflammation in NOD2-deficient mice and patients with CD was attributed to the impaired bactericidal activity of Paneth cells.⁶⁶ Furthermore, reciprocal microbiota transplantation was found to reduce the risk of colitis or colorectal cancer in Nod2−/− mice.⁶⁷ Lastly, NLRP12, a negative regulator of inflammation, was identified in an experimental colitis model and patients with IBD.⁶⁸ NLRP12 suppresses the excessive production of inflammatory cytokines in the intestines and decreases the susceptibility to colitis by maintaining commensal variety and protective microbiota. The sequencing of bacterial 16S rRNA confirmed that NLRP12−/− may result in the loss of protective gut commensal strains (Lachnospiraceae) and an increase in Escherichia coli strains (Erysipelas), which can be reversed via the administration of beneficial commensal Lachnospira isolates or antibodies targeting inflammatory cytokines. Additionally, NLRP12-deficient mice could be treated with microbiome transplants or antibodies targeting inflammatory cytokines.⁵³ The above studies on the microbiome in NLRP12-deficient mice resemble those of human IBD patients.^69
-71

To date, accumulating evidence has demonstrated the impact of NLRs on the gut microbiota and IBD and illustrated the potential of manipulating the gut microbiota in the treatment of IBD. Therefore, there is great interest in the possible benefits of microbiome-modulating interventions, such as probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and the role of genetic manipulation in the treatment of IBD. However, the underlying mechanisms of how genetic alterations affecting NLRs affect gut microbiota biodiversity are still not fully understood. Additionally, the relationship between gut dysbiosis and IBD is complex and dynamic, rather than a simple causal relationship.

Role of NLRs in modulating the intestinal mechanical barrier

Gut mechanical barrier dysfunction is a consistent feature of IBD.⁷² This barrier is composed of intact intestinal epithelial cells, the AJC, and the lamina propria.⁷³ AJC maintains intestinal homeostasis mainly by controlling the permeability of intestinal epithelial cells to limit the transport of relatively large molecules.^74,75 Accumulating data support a correlation between NLRs and the integrity of the intestinal mechanical barrier. protects mice against increased intestinal mucosal permeability caused by AJC dysfunction by regulating myosin light chain kinase (MLCK) signaling^76,77 In Caco-2, a small intestinal eNOD2pithelial cell similar in structure and function to differentiation, NLRP3 weakens the cell’s trans epithelial resistance by reducing the expression of claudin-1, occludin, and ZO-1, while increasing the expression of claudin-2 and repositioning occludin and ZO in Caco-2 monolayer.⁷⁸ Likewise, the NLRP3 inflammasome was activated in antibiotic-exposed Caco-2 and mice, resulting in decreased expression of claudin and disrupted ZO-1 morphology.⁷⁹ In addition to the destruction of AJC, abnormal death of intestinal epithelial cells is a major cause of intestinal mucosal mechanical barrier dysfunction.⁸⁰ Autophagy has been shown to regulate cytokine-induced programmed cell death in intestinal epithelial cells, limiting intestinal inflammation. The inflammasome and autophagy are mutually regulated, and this bidirectional regulation provides the necessary checks and balances between host defenses against inflammatory responses and the prevention of excessive inflammation in organ and tissue damage and inflammatory diseases. NLRP6 deficiency results in defective autophagy in goblet cells and reduced mucin secretion in the lumen of the large intestine.⁸¹ When NLRP6-deficient mice were treated with DSS, they became more susceptible to serious colitis due to a reduction in IL-18 expression by intestinal epithelial cells (IECs), and pathological damage increased compared to wild-type animals.⁸² Akin to NLRP6, NLRP3 performs a protective function for intestinal epithelial cells. Compared to wild-type mice, NLRP3-deficient mice are more likely to suffer from C. rodentium infections.⁸³ Simultaneously, activating the NLRP3 inflammasome can induce the compensatory proliferation of epithelial cells, protecting the integrity of the epithelial layer during DSS-induced colitis.⁸⁴ NLRC4 is a double-edged sword. On the one hand, NLRC4 can restrict infections by S.typhimurium by activating pyroptosis and forcing infected intestinal epithelial cells to enter the lumen.⁴³ On the other hand, excessive NLRC4 results in too much pyroptosis, which triggers small intestinal damage.⁸⁵

Role of NLR in regulating mucosal immunity

The intestine serves as the largest immune organ in mammals, containing 90% of the immunocompetent cells. The intestinal mucosal immune barrier comprises gut-associated lymphoid tissues (such as Peyer’s patches and mesenteric lymph nodes), cells [such as innate immune cells (neutrophils, monocyte/macrophages, dendritic cells, mast cells, and innate lymphoid cells) and adaptive immune cells (B and T cells)], and molecules (such as immunoglobulins and AMPs).²² Moreover, epithelial cells are increasingly viewed as an integral part of the immune barrier.

NLRP1 was the first pattern recognition receptor (PRR) discovered to form an inflammasome, and genome-wide association studies have identified NLRP1 mutations linked with IBD.⁸⁶ Previous evidence showed that NLRP1b−/− mice showed a significant increase in the incidence of colitis, infections, and colitis-related tumorigenesis via the modulation of IL-1β and IL-18 levels. Moreover, the wound healing and defense responses in DSS-induced colitis and lipopolysaccharide (LPS)-stimulated cellular inflammation in mouse macrophages might be caused by the downregulation of NLRP1 expression.⁴⁶ Similarly, gut-barrier defects and excessive intestine-related lymphoid tissue activation are features of NOD2 deficiency in humans and mice.³⁸ Further investigations revealed that hyperresponsive macrophages and colitis promoted NOD2 signaling in IL-10-deficient mice, and a deficiency of NOD2 ameliorated chronic colitis in IL-10−/− mice.⁸⁷ Additionally, NOD2−/− can lead to a steady-state imbalance, inactivated fibroblasts, and inflammatory macrophages, manifested by the increased expression of aberrant activation-related transcriptomes caused by the upregulation of upstream transcription factors such as WT1 and STAT3, and it causes the gp130 family to upregulate the expression of certain genes (IL-11, IL-6, OSM, etc), thereby increasing the risk of intestinal stenosis.⁸⁸ Moreover, NLRP3 is the most widely studied immune regulator in NLRs, although its role is controversial. Chen et al. showed that the interaction of the NLRP3 inflammasome with NEK7 promotes IBD by mediating NF-κB signaling to regulate macrophage apoptosis.⁴⁹ By contrast, NLRP3-inflammasome activation can facilitate the restoration and reproduction of the intestinal mucosa, which could be related to enhanced levels of caspase-1, IL-1β, and IL-18.⁸⁹ IL-1β promotes the production of IL-22 and IL-10 to maintain epithelial integrity.^90,91 IL-18 and IL-1β were shown to promote compensatory epithelial cell proliferation and reduce DSS-induced inflammatory colon injury.⁸³ Intriguingly, another study showed that uncontrollably active NLRP3 inflammasomes neutralize intestinal inflammation by inducing the production of Tregs and reshaping the gut microbiota in NLRP3-mutant mice.⁵⁰ In addition to the above NLRs, NLRP6 is also an important regulator of IBD. NLRP6−/− mice showed an increase in the number of CD45+cells in the lamina propria, proliferation of colonic crypts, enlargement of Peyer’s patches, and formation of germinal centers.⁵⁶ These mice exhibited increased mucosal permeability and were unable to recover from colitis.^82,92

In summary, NLRs play critical roles in immune cell development and function through multiple canonical immune regulatory mechanisms, including caspase-1, RIP2 kinase, mitogen-activated protein kinase (MAPK), and NF-κB signal pathway. However, with the deepening of the research on NLRs in IBD, the functions of these proteins have also become more diverse, but the exact roles of some NLRs in IBD are still controversial and deserve further study. In addition, the biochemical processes regulating NLRs activation and downstream functions remain to be further investigated.

Targeting NLRs with botanicals in IBD therapy

Many synthetic drugs and monoclonal antibodies are currently administered in the clinic to treat IBD, such as NF-κB inhibitors (e.g. sulfasalazine), TNF-α antagonists (e.g., infliximab), and glucocorticoids (e.g. prednisolone). However, the therapeutic effects of these drugs are unsatisfactory, as their long-term administration can produce severe side effects, leading to poor patient acceptance and compliance.^93–95 Therefore, exploring safe and effective drugs has become an urgent task for the treatment of IBD patients.

NLRs are important regulators of intestinal mucosal homeostasis and are promising therapeutic targets for IBD. NLRs have regulatory effects on multiple signaling molecules explicitly related to IBD diseases, such as NF-κB, ASC, caspase-1, MAPK, IL-1β, TNF-α, IL-6and IL-18 (Figure 2). The apparent breadth and magnitude of NLRs’ involvement illustrate the apparent centrality of this protein family. As of November 2019, 82 patents were pending for potential therapeutic NLRs modulators, and 22 patents had been granted.⁹⁶ Additionally, there are multiple phase I clinical trials of NLRP3 inhibitors for CD that have been registered in public databases by Novartis.⁹⁷

Figure 2.

The mechanism of NLRs in the pathogenesis of IBD.

NPs, including dietary compounds, herbal formulas, and their extracts, have been known to have unique curative effects in the management of chronic inflammatory diseases for thousands of years. Numerous experiments in vitro and in vivo have indicated that some active ingredients in botanicals and NPs perform anti-IBD functions by regulating NOD-like receptor signaling, with few toxic side effects compared to synthetic treatments. In this section, we review the current findings on targeting NLRs with botanicals in IBD intervention (Table 2).

Table 2.

Targeting NLRPs with botanicals in IBD therapy.

Agent	Experimental subjects	Outcomes	Potential mechanisms	References
Wogonoside	Female BALB/c mice (DSS), THP-1 cells	Inflammatory cytokines↓, inflammatory cell infiltration↓, colonic pathological damage↓	Blocking activation of NF-κB and NLRP3 inflammasome.	Sun et al.⁹⁸
Flavonoid VI-16	Male C57BL/6 J mice (DSS), Macrophages	Colonic pathological damage↓, inflammatory cytokines↓	Suppressing ROS/Txnip/NLRP3 signaling pathway.	Zhao et al.⁹⁹
Curcumin	Female C57BL/6 mice (DSS), Macrophages	DAI↓, inflammatory cytokines↓, colonic pathological damage↓	Blocking activation of NLRP3 inflammasome and ASC oligomerization.	Gong et al.¹⁰⁰
Procyanidin	Male C57BL/6 mice (DSS), Macrophages	Colonic pathological damage↓, inflammatory condition↓	Suppressing activation of MMP9, NF-κB, and NLRP3 inflammasome.	Chen et al.¹⁰¹
Naringin	Male C57BL/6 mice (DSS), RAW264.7 cells	Inflammatory cytokines↓, disease severity↓, DAI↓	Activating PPARγ and suppressing NF-κB, MAPK, and NLRP3-inflammasome activation.	Cao et al.¹⁰²
Phloretin	Male C57BL/6 mice (DSS)	Escherichia coli and Lactobacillus levels rebalanced, gut epithelial barrier integrity↑	Upregulating ZO-1 and occludin expression, inhibiting NLRP3 inflammasome activation.	Zhang Z et al.¹⁰³
Genistein	C57BL6/J mice (DSS), Macrophages	Pro-inflammatory mediator production↓, disease severity↓, inflammatory cell infiltration↓	Inhibiting NLRP3 inflammasome by regulating TGR5-cAMP pathway.	Chen et al.¹⁰⁴
Cardamonin	Male C57BL/6 mice (DSS),Male BALB/c mice (TNBS:2,4,6-trinitrobenzenesulfonic acid)	Myeloperoxidase activity↑, DAI↓, colonic pathological damage↓	Activating AhR/Nrf2/NQO1 pathway and inhibiting NLRP3-inflammasome activation.	Wang et al.¹⁰⁵
Alpinetin	Female BALB/c mice (DSS),THP-1 cells	Diarrhea and colonic histological injury↓, inflammatory cytokines↓	Downregulating TLR4, NF-κB, and NLRP3-inflammasome expression.	He et al.¹⁰⁶
Formononetin	Male C57BL/6 mice (DSS),HCT-116 cells	Epithelial cell injury↓, disease severity↓	Increasing tight junction proteins expressions and inhibiting the NLRP3 pathway.	Liu et al.¹⁰⁷
Apigenin	Male C57BL/6 mice (DSS)	Inflammatory cytokines↓, colonic pathology damage↓.	Reprograming the gut microbiota through regulating NLRP6.	Radulovic et al.¹⁰⁸
Paeoniflorin	C57BL/6 mice (DSS), RAW264.7 cells	Gram-positive bacteria count and gram-positive bacterial infiltration↓, disease severity↓.	Inhibiting gram-positive bacteria-dependent MDP–NOD2 pathway.	Luo et al.¹⁰⁹
Toosendanin	Male C57BL/6 mice (DSS)	M1 macrophage polarization↓, disease severity↓	Upregulating HO-1/Nrf2 expression and inhibiting NLRP3 inflammasome activation.	Fan et al.¹¹⁰
Asiatic acid	Female C57BL/6 mice (DSS), THP-1 cells	Inflammatory cytokines↓, disease severity↓	Suppressing mitochondria-mediated NLRP3-inflammasome activation.	Guo et al.¹¹¹
Dihydroartemisinin	Male C57BL/6 mice (DSS)	DAI↓, inflammatory cytokines↓, disease severity↓	Inhibiting the phosphorylation of NF-κB p65 and p38 MAPK, and NLRP3-inflammasome activation.	Liang et al.¹¹²
Ginsenoside Rg1	C57BL/6 mice (DSS)	DAI↓, pro-inflammatory cytokines levels↓, colonic damage scores↓.	Activating TLR4-NLRP12-NF-κB pathway.	Zhu et al.¹¹³
Celastrol	Male SD rats (DSS)	DAI and MDI↓, colonic histological damage↓, inflammatory cytokines↓	Modulating HSP90 and inducing autophagy to enhance NLRP3 sensitivity to CP-456773.	Saber et al.¹¹⁴
Libertellenone M	Female C57/BL6 mice (DSS),RAW264.7 cells.	DAI↓, disease severity↓, inflammatorycytokines↓.	Inhibiting the nuclear translocation of NF-κB and the assembly of NLRP3 inflammasome	Fan et al.¹¹⁵
Ginsenoside Rk3	male C57BL/6 mice (DSS)	Clinical symptoms↓, inflammatory cell infiltration↓, pro-inflammatory cytokines↓,	Inhibiting NLRP3-inflammasome activation	Tian et al.¹¹⁶
Palmatine	Male BALB/C mice (DSS), THP-1 cells	DAI↓, colonic inflammation↓, disease severity↓.	Facilitating PINK1/Parkin-driven mitophagy-mediated NLRP3-inflammasome inactivation.	Mai et al.¹¹⁷
Fumigaclavine C	female C57BL/6 mice (DSS), THP-1 cells	Disease severity↓, inflammatory cytokines↓, DAI↓.	Suppressing NF-kB, STAT3, STAT1, and NLRP3-inflammasome activation.	Guo et al.¹¹⁸
Evodiamine	Male C57BL/6 mice (DSS)	DAI↓, Escherichia coli, and Lactobacillus levels rebalanced, colonic pathological damage↓.	Suppressing NF-κB and NLRP3-inflammasome activation.	Shen et al.¹¹⁹
Carboxyamidotriazole	Female SD rats (TNBS)	Intestinal inflammatory and permeability↓, colonic pathological damage↓.	Inhibiting NLRP3-inflammasome and NF-κB activation.	Du et al.¹²⁰
Compound 1	Female C57BL/6 mice (DSS), THP-1 cells	Mucosal damage↓, inflammatory cell infiltration↓, CD11b+ infiltrating cells↓	A novel potent Nrf2/ARE inducer, inhibiting NLRP3-inflammasome activation.	Wang et al.¹²¹
Chlorogenic acid	BALB/c mice (DSS)RAW264.7 cells.	Colonic inflammation↓, disease severity↓.	Suppressing miR-155/NF-κB/NLRP3 pathway.	Zeng et al.¹²²
Bergenin	Male Wistar rats (TNBS)	MPO↓, inflammatory cytokines↓, Disease severity↓.	Blocking pSTAT3, NF-κB canonical, and NLRP3/ASC pathways.	Lopes de Oliveira et al.¹²³
Brusatol	Male SD rats (TNBS), RAW264.7 cells.	Colonic pathology damage↓, oxidative stress↓, DAI↓.	Suppressing NF-κB and NLRP3 activation and enhancing Nrf2 expression	Zhou et al.¹²⁴
Fraxinellone	Male C57BL/6 mice (DSS), THP-1 cells	Macrophage infiltration↓, colonic pathology damage↓, inflammatory cytokines↓.	Suppressing NF-κB signaling and NLRP3 inflammasome activation.	Wu et al.¹²⁵
VitD3	Male C57BL/6 mice (DSS), Macrophages	Macrophage infiltration↓, colon inflammation↓, CD4+ T cells generation↓.	Inhibiting VDR/ NLRP3/ASC pathway and NLRP3-NEK7 interaction.	Cao et al.¹²⁶
MLB	Male C57BL/6 J mice (DSS).	Colonic pathology damage↓, inflammatory cytokines↓.	Inhibiting the activation of NRLP3/ASC/caspase-1 pathway.	Jiang et al.¹²⁷
Physalin B	Male BALB/c mice (DSS), RAW 264.7 cells	Colonic pathology damage↓, inflammatory cytokines↓, DAI↓.	Suppressing the activation of STAT3, β-arrestin1, and NLRP3 inflammasome.	Zhang et al.¹²⁸
Oryzanol	SD rats (DSS), Caco-2 cells	Gut-barrier damage of colitis rats↓abundances of Alloprevotella, Roseburia, Treponema, Muribaculaceae, and Ruminococcus↑.	SuppressingTLR4/NF-κB/NLRP3 signaling axis.	Xia et al.¹²⁹
Munronoid I	Female wild-type C57BL/6 mice, Mouse peritoneal macrophages, MODE-K cells	Colonic pathology damage↓, disease severity↓.	Promoting K48-linked ubiquitination and degradation of NLRP3	Ma et al.¹³⁰
Artemisinin analog SM934	Female C57BL/6 mice, HT-29 and Caco-2 cells.	Intestinal barrier function↑, intestinal epithelial cell apoptosis↓.	Suppressing NLRP3/NF-κB/MAPK signal axis	Shao et al.¹³¹
Soy isoflavones	Male C57BL/6 mice (DSS), NCM460 cells	Pro-inflammatory cytokines↓, colonic pathology damage↓.	Inhibiting ERα/NLRP3 inflammasome activation.	Gao et al.¹³²
LEP	Male ICR mice	Oxidative stress damage↓, disease severity↓.	Regulating PPARγ/NF-κB and IL-6/STAT3 pathways and inhibiting NLRP3 inflammasome.	Zong S et al.¹³³
QCWZD	Male SD rats (DSS)	Butyricimonas, Blautia, and Odoribacter↑, disease severity↓.	Inhibiting the activity of the TLR4/Blimp-1 pathway to promote NLRP12 expression	Sun et al.¹³⁴
QRJPD	Male C57BL/6 J mice	Colonic pathology damage↓, disease severity↓.	Inhibit activation of the NLRP3 inflammasome	Zhang et al.¹³⁵
APS	Male C57BL/6 mice (DSS)	Colonic pathology damage↓, disease severity↓.	Inhibiting the NLRP3 signaling pathway	Tian et al.¹³⁶
LEM	Male C57BL/6 mice (DSS)	DAI↓, Inflammatory cell infiltration↓, intestinal barrier integrity↑.	Modulating NF-κB and MAPK pathways and Inhibiting NLRP3 inflammasome activation.	Zong et al.¹³⁷
RGE + EKN	C57BL/6 mice (DSS).	DAI↓, oxidative stress↓, pro-inflammatory cytokines↓, intestinal mucosal function↑.	Inhibiting TLR4/ NF-κB and NLRP3 inflammasome pathways	Saba et al.¹³⁸
CGB	C57BL/6 mice (DSS)	Inflammatory cell infiltration↓, colonic pathology damage↓.	Suppressing the NLRP3 signaling pathway and restores the expression of occludin and claudin-1.	Mahmoud et al.¹³⁹
Platycodon grandiflorum root	Macrophages, Intestinal epithelial cells, Mice (DSS)	Inflammatory cytokines↓,colonic pathology damage↓.	Inhibiting NF-κB signaling pathway and the expression of NLRP3 inflammasomes by activating AMP-activated protein kinase	Wang et al.¹⁴⁰

APS, astragalus polysaccharide; CGB, Canna × generalis L.H. Bailey; EKN, epimedium Koreanum Nakai; LEM, lycium ruthenicum Murray; LEP, lachnum polysaccharide; MAPK, mitogen-activated protein kinase; MLB; Magnesium lithospermate B; NF-κB, nuclear factor kappa B; RGE, Red ginseng extract; QCWZD, Qingchang Wenzhong decoction; QRJPD, Qingrejianpi decoction.

Flavonoids

Flavonoids have been reported to encompass multiple biological activities, including immune adjustment, scavenging free radicals, the changing of the microbiota constitution, antiapoptotic, and the restoring of damaged epithelial barriers. For this reason, flavonoids may be a promising approach for IBD management. For instance, wogonoside, a natural flavonoid isolated from Scutellaria baicalensis, attenuates DSS-induced colitis in mice through the inhibition of NF-κB and NLRP3 inflammasome.⁹⁸ Similarly, Flavonoid VI-16 (a synthetic flavonoid compound), selectively inhibits Txnip-dependent activation of NLRP3 inflammasome to alleviate oxidative stress in colonic macrophages, thereby reducing DSS-induced colitis.⁹⁹ Other flavonoids NLRP3 signaling inhibitors, such as curcumin, procyanidin, naringin, phloretin, cardamonin, alpinetin, genistein, and formononetin, have likewise been shown to be effective in the treatment of colitis.^100
–107 Other flavonoid NLRs inhibitors also have a potentially preventive or therapeutic effect on colitis. Apigenin, a common dietary flavone, protects against gut inflammation by modulating the intestinal microbiota constituents through NLRP6 and C-type lectin Reg3b in mice.¹⁰⁸

Terpenoids

Terpenoids constitute the largest class of NPs and are a rich reservoir of candidate compounds for drug discovery. Several preclinical studies have provided evidence that terpenoids are useful in IBD. Paeoniflorin, a natural monoterpenoid isolated from Paeonia lactiflora Pall, was proven to facilitate intestinal mucosal barrier protection in a DSS-induced colitis model. Detailed studies indicated that paeoniflorin ameliorates DSS-induced colitis in mice by decreasing the infiltration of gram-positive bacteria through the regulation of the gram-positive-bacterium-dependent MDP–NOD2 pathway.¹⁰⁹ Toosendanin is derived from the fruits or bark of Melia toosendan Sieb. Et Zucc (Meliaceae), potently blocked NLRP3 inflammasome activation via Nrf2/HO-1 signaling in mouse IBD models.¹¹⁰ Asiatic acid was demonstrated to block the ROS–NLRP3–caspase-1–IL-1β cascade in macrophages and experimental mouse colitis models.¹¹¹ Dihydroartemisinin prevents DSS-induced colitis in mice by effectively blocking p38 MAPK signaling and NLRP3-inflammasome activation.¹¹² Ginsenoside Rg1, a pharmacologically active component of ginseng, effectively blocked the expression of NLRP12 and NF-κB signaling and reduced the inflammation of DSS-induced colitis in mice.¹¹³ Celastrol, a natural triterpenoid extracted from the root bark of Tripterygium wilfordii Hook. f. Celastrol, protected mice against colitis by inhibiting the activation of the NLRP3 inflammasome signaling.¹¹⁴ Libertellenone M, a hippocampal diterpenoid from the marine-derived fungus Stibella fimetaris, inhibited NLRP3-inflammasome activation in a mouse model of IBD.¹¹⁵In addition, Ginsenoside Rk3, selectively blocked NLRP3 inflammasome activation, leading to reduced TNF-α, IL1β, and IL-6 production in a mouse model of IBD.¹¹⁶

Alkaloids

An increasing number of recent studies have reported that alkaloids are effective in treating intestinal inflammatory disorders. Palmatine, originally isolated from medicinal rayon fibers, promotes PINK1/Parkin-mediated mitochondrial autophagy and inhibits NLRP3 inflammatory vesicle activation, leading to a decrease in IL-1β, thereby alleviating DSS-induced colitis in mice.¹¹⁷ Fumigaclavine C, isolated from Aspergillus fumigatus cultures, inhibits the formation of the NLRP3 inflammasome to alleviate DSS-induced colitis.¹¹⁸ Evodiamine, an alkaloidal compound isolated from the traditional Chinese medicine Evodia rutaecarpa (Juss.), exerts therapeutic activities in treating DSS-induced UC mice by regulating NF-κB signaling and the NLRP3 inflammasome and inhibiting the production of TNF-α, IL-1β, and IL-6.¹¹⁹ Carboxyamidotriazole, an inhibitor of non-voltage-gated calcium channels, maintains intestinal integrity by inhibiting the expression of inflammatory cytokines, NF-κB signaling, and NLRP3-inflammasome activation in TNBS-induced mice.¹²⁰ 3-(2-Oxo-2-phenylethylidene)−2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(1 1bH)-one (compound 1), a new potential Nrf2/ARE inducer, reduces DSS-induced inflammatory cell infiltration and colon pathological damage by activating Nrf2 to block the NLRP3 initiation step.¹²¹

Phenylpropanoids

Phenylpropanoids are attractive molecules for the development of new drugs against a wide range of diseases, such as those related to inflammatory processes. In IBD, compounds from the plant phenylpropanoid metabolic pathway have yielded promising associations. Chlorogenic acid, a dietary polyphenol from the hydroxycinnamic acid family, widely exists in medicinal herbs and human diets. Zeng et al. found that chlorogenic acid can maintain intestinal microecology and immune balance by suppressing NLRP3-inflammasome-related signaling in DSS-induced mice. Furthermore, chlorogenic acid inhibits RAW264.7 cell activation by reducing the expression of p-NK-κB and NLRP3-inflammasome proteins, which depend on the downregulation of miR-155 expression.¹²² Bergenin, a natural secondary metabolite abundant in Shiso Bergen, Mallotus japonicus, and Gabonese Shagroti, prevents non-classical and classical NLRP3/ASC inflammatory access by regulating pSTAT3 and NF-κB signaling to reverse TNBS-induced colon tissue damage in acute colitis in mice.¹²³ Brusatol, a quassinoid compound isolated from Brucea javanica, has protective effects against TNBS-induced colitis that are closely related to the mechanism through inhibition of NF-κB and NLRP3-mediated inflammatory responses and regulation of Nrf2-mediated oxidative stress.^124,125

Other compounds

Apart from the NPs mentioned above, many other polysaccharides, proteins, amino acids, and other active NPs also exert anti-IBD biological activities by regulating NLR-mediated inflammatory responses. Fraxinellone, a product of limonoids originating from the root bark of Dictamnus dasycarpus, potently blocked the activation of NLRP3 inflammasome and NF-κB signaling in macrophage activation and alleviate intestinal inflammatory responses.¹²⁶ 1,25-Dihydroxy Vitamin D3 (VitD3) is a steroid hormone with anti-proliferative/immunomodulatory effects, inhibited the oligomerization of the caspase recruitment domain (ASC) and specifically inhibits the activation of NLRP3. Subsequently, NLRP3 was found that NLRP3 mediates the inhibition of vitamin D receptors on caspase 1 activation and IL-1 secretion in DSS-induced UC mice.¹²⁷ Magnesium lithospermate B is a salvianolic compound derived from Salvia miltiorrhizae radix, which protects the colonic mucosa from acute and chronic colitis by inhibiting the NLRP3/ASC/caspase-1 pathway in DSS-induced mice.¹²⁸ Physalin B is a withanolide compound abundant in Physalis alkekengi L. var. franchetii (Mast.) Makino (a nutraceutical and Chinese herbal medicine), ameliorates general symptoms and colon pathological damage by inhibiting the activation of STAT3, β-arrestin1, and NLRP3 inflammasomes in DSS-induced colitis mice.¹²⁹ Oryzanol, a nutrient component of cereal grains, attenuates intestinal barrier damage and inflammatory responses by modulating the DSS-induced intestinal microbiota-TLR4/NF-κB/NLRP3 signaling axis in UC rats.¹³⁰ Monroxone I is a diterpenoid compound isolated and purified from the Meliaceae family that inhibited pro-inflammatory factor production and typical apoptosis of mouse peritoneal macrophages by promoting k48 ubiquitination and NLRP3 degradation in DSS-induced mice.¹³¹ Artemisinin analog SM934, a new water-soluble artemisinin analog, protects mice with colitis from TNBS-induced intestinal barrier disruption by inhibiting epithelial cell apoptosis and focal death through regulation of the NLRP3/NF-κB/MAPK signaling axis.¹³²

Plant extracts

Except for isolated phytochemicals, other botanicals and extracts may also have potential preventive or therapeutic effects on IBD driven by NLRs. Soy isoflavones (SIFs) are selective estrogen receptor modulators with anti-inflammatory activity. In IBD, SIFs ameliorate DSS-induced colitis by inhibiting ERα expression and the NLRP3-inflammasome pathway.¹³³ Lachnum polysaccharide (LEP) alleviates DSS-induced colitis by suppressing NLRP3 activation and downregulating ASC, caspase-1, and IL-1β levels.¹³⁴ Qingchang Wenzhong Decoction (QCWZD) is a traditional Chinese herbal formula widely used in clinical practice for the treatment of IBD. QCWZD protected against IBD by inhibiting TLR4/Blimp-1 pathway activity promotes NLRP12 expression and selectively ameliorates beneficial strains such as Odoribacterium, Braunschweiger, and Clostridium butyricum while reducing intestinal pathogenic bacteria, including Dora and Clostridium reaching.¹³⁵ Qingrejianpi Decoction can reduce NLRP3 expression, reduce the secretion of inflammatory cytokines, and inhibit inflammatory infiltration of immune cells to inhibit the occurrence and development of IBD.¹³⁶ Astragalus polysaccharide, the main active ingredient of Astragalus membranaceus, effectively attenuated colitis in mice by inhibiting the expression of apoptotic point proteins containing the C-terminal caspase collecting domain, caspase-1, NOD-like receptor protein 3, IL-18, and IL-1β.¹³⁷ Lycium ruthenicum Murray is an edible ethnomedicinal and nutritional food that inhibits the NF-κB and MAPK pathways, suppresses NLRP3 inflammasome activation, and restores intestinal immune homeostasis by enhancing intestinal antioxidant defenses.¹³⁸ Red ginseng extract (RGE) +Epimedium Koreanum Nakai (EKN) synergistically reduce the plasma and tissue levels of cytokines and pro-inflammatory mediators by inhibiting the expression of NF-κB of activated B cells and the nucleotide-binding domain of NLRP3 in DSS-induced colitic mice. In vitro, RGE + EKN can dramatically decrease the levels of nitric acid (NO), cytokines, and pro-inflammatory mediators by downregulating the expression of MAPK and NF-κB in RAW 264.7.¹³⁹ Canna × generalis L.H. Bailey (CGB) is a traditional anti-inflammatory agent. Studies have confirmed that CGB rhizome extract restores DSS-induced intestinal mucosal dysfunction, reduces oxidative stress, and suppresses inflammatory responses in mice with colitis by inhibiting the NLRP3 inflammasome and TLR4/NF-κB pathways.¹⁴⁰ Platycodon grandiflorus is a dual-use herb for medicinal and food purposes. The fermentation solution of Platycodon grandiflorus root reduces the level of inflammatory factors in serum and the expression of inflammatory factor mRNA in the intestine by inhibiting the AMPK/NF-κB/NLRP3 pathway, regulates the polarization of M1/M2 macrophages, and increases the expression of tight junction protein mRNA in intestinal epithelial cells in a mouse model of IBD.¹⁴¹

Conclusions and perspectives

IBD has become a serious public health problem affecting human health and is becoming increasingly prevalent around the world. Due to its therapeutic difficulties and the need for long-term treatment, IBD has become a hot topic in the global medical field. The current consensus is that disruption of the intestinal mucosal barrier leading to the displacement of bacteria, which in turn causes a series of immune and inflammatory responses is thought to be the pathogenesis of IBD. Repairing the intestinal mucosal barrier is a highly coordinated process that involves the intestinal flora, TJs, inherent immune recognition, and self-renewal of epithelial cells. Several recent studies highlighted the important benefits of NLRs for gut health.

NLRs maintain the intestinal mucosal barrier’s integrity and homeostasis by controlling the diversity and stability of the gut microbiome, modulating inflammatory signaling events, and amplifying IEC crosstalk with immune cells. Experimental and clinical evidence indicates that NLRs mediate the establishment and homeostatic regulation of the intestinal mucosal barrier. NLRs have become an important target for the treatment of IBD and drug screening. However, diverse mechanisms may contribute to mucosal cures via NLRs. Consequently, there is a demand for further research to specifically illustrate the benefits of the various NLR-mediated signal-conduction mechanisms in the moderation of gut homeostasis and IBD.

This review focused on NPs that can modulate NLRs, making them promising candidates for the development of lead structures in anti-IBD drugs. However, most NPs targeting NLRs lack isoform selectivity, which is important for determining their potential use as therapeutic agents. Nevertheless, the structure types presented in this review offer a well-founded basis indicating that screening and chemical modifications of NPs will, in the future, identify not only more specific inhibitors with fewer adverse side effects but also important characteristics for the elucidation of NLRs’ functions concerning IBD treatment.

In the future, further studies are needed to explain the precise molecular modes of the functions of these botanicals in the activation of NLRs. In addition, the potential toxicities and drug-to-drug interactions of these botanicals in the human body should be explored. Furthermore, the anti-IBD effects of botanicals have not been clinically verified. Generally speaking, since the presence of NLRs is important in both the development and progression of IBD, addressing related NLR modulators is a promising starting point for developing new and potent anti-IBD drugs.

Footnotes

Acknowledgements

None.

Declarations

ORCID iD

Gang Pei

References

Shi

Hamidi

, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778.

Porter

Kalla

GT.

Ulcerative colitis: recent advances in the understanding of disease pathogenesis. F1000Research 2020; 9: 294.

Turpin

Goethel

Bedrani

, et al. Determinants of IBD Heritability: genes, bugs, and more. Inflamm Bowel Dis 2018; 24: 1133–1148.

Spalinger

Sayoc-Becerra

Ordookhanian

, et al. The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions. J Crohns Colitis 2021; 15: 471–484.

Lei-Leston

Murphy

Maloy

KJ.

Epithelial cell inflammasomes in intestinal immunity and inflammation. Front Immunol 2017; 8: 1168.

Sun

Yang

Rogers

, et al. AMPK improves gut epithelial differentiation and barrier function via regulating Cdx2 expression. Cell Death Differ 2017; 24: 819–831.

Rubin

SJS

Bai

Haileselassie

, et al. Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases. Nat Commun 2019; 10: 2686.

Guo

Gibson

Ting

JPY

. Gut microbiota, NLR proteins, and intestinal homeostasis. J Exp Med 2020; 217: e20181832.

Mehandru

Colombel

JF.

The intestinal barrier, an arbitrator turned provocateur in IBD. Nat Rev Gastroenterol Hepatol 2021; 18: 83–84.

10.

Khatri

Kalyanasundaram

Therapeutic implications of inflammasome in inflammatory bowel disease. FASEB J 2021; 35: e21439.

11.

Peng

, et al. Shepherd’s purse polyphenols exert its anti-inflammatory and antioxidative effects associated with suppressing MAPK and NF-κB pathways and heme oxygenase-1 activation. Oxid Med Cell Longev 2019; 2019: 1–14.

12.

Tao

, et al. Osthole protects against Ang II-induced endotheliocyte death by targeting NF-κB pathway and Keap-1/Nrf2 pathway. Am J Transl Res 2019; 11: 142–159.

13.

Seelbinder

Chen

Brunke

, et al. Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria. Microbiome 2020; 8: 133.

14.

Kostic

Xavier

Gevers

The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146: 1489–1499.

15.

Kayama

Okumura

Takeda

Interaction between the Microbiota, epithelia, and immune cells in the intestine. Annu Rev Immunol 2020; 38: 23–48.

16.

Chassaing

Koren

Goodrich

, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Our Nat 2015; 519: 92–96.

17.

Willems

RPJ

van Dijk

Ket

JCF

, et al. Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis. JAMA Intern Med 2020; 180: 561–571.

18.

Ostaff

Stange

Wehkamp

Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med 2013; 5: 1465–1483.

19.

Zihni

Mills

Matter

, et al. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol 2016; 17: 564–580.

20.

Hartsock

Nelson

WJ.

Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008; 1778: 660–669.

21.

Schneeberger

Lynch

RD.

The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004; 286: C1213–C1228.

22.

Jin

Chen

The effects of secretory IgA in the mucosal immune system. Biomed Res Int 2020; 2020: 1–6.

23.

Colgan

Furuta

Taylor

CT.

Hypoxia and innate immunity: keeping up with the HIFsters. Annu Rev Immunol 2020; 38: 341–363.

24.

Ren

Wang

Yin

, et al. Glutamine-induced secretion of intestinal secretory immunoglobulin A: a mechanistic perspective. Front Immunol 2016; 7: 503.

25.

Corthésy

Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 2013; 12: 661–665.

26.

Chen

Cui

, et al. Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease. Front Immunol 2021; 12: 761981.

27.

Ting

JPY

Lovering

Alnemri

, et al. The NLR gene family: a standard nomenclature. Immunity 2008; 28: 285–287.

28.

Chu

Gao

, et al. Expression profiles of NOD-like receptors and regulation of NLRP3 inflammasome activation in Toxoplasma gondii-infected human small intestinal epithelial cells. Parasit Vectors 2021; 14: 153.

29.

Zheng

The emerging roles of NOD-like receptors in antiviral innate immune signaling pathways. Int J Biol Macromol 2021; 169: 407–413.

30.

Kufer

Kremmer

Banks

, et al. Role for erbin in bacterial activation of Nod2. Infect Immun 2006; 74: 3115–3124.

31.

Hasegawa

Yamazaki

Kamada

, et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol 2011; 186: 4872–4880.

32.

Hara

Seregin

Yang

, et al. The NLRP6 inflammasome recognizes lipoteichoic acid and regulates gram-positive pathogen infection. Cell 2018; 175: 1651–1664.e14.

33.

Chen

GY.

Role of nlrp6 and nlrp12 in the maintenance of intestinal homeostasis. Eur J Immunol 2014; 44: 321–327.

34.

Mandal

Rajarammohan

Kaur

ROS accumulation and associated cell death mediates susceptibility to Alternaria brassicae in Arabidopsis accessions. Physiol Mol Plant Pathol 2019; 107: 51–59.

35.

Saur

IML

Panstruga

Schulze-Lefert

NOD-like receptor-mediated plant immunity: from structure to cell death. Nat Rev Immunol 2021; 21: 305–318.

36.

Chen

Shaw MH and Nunez

The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 2008; 68: 10060–10067.

37.

Le Bourhis

Magalhaes

Selvanantham

, et al. Role of Nod1 in mucosal dendritic cells during Salmonella pathogenicity island 1-independent Salmonella enterica serovar Typhimurium infection. Infect Immun 2009; 77: 4480–4486.

38.

Al Nabhani

Lepage

Mauny

, et al. Nod2 deficiency leads to a specific and transmissible mucosa-associated microbial dysbiosis which is independent of the mucosal barrier defect. J Crohns Colitis 2016; 10: 1428–1436.

39.

Jiang

Wang

Zeng

, et al. Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med 2013; 210: 2465–2476.

40.

Richardson

Sodhi

Russo

Nucleotide-binding oligomerization domain-2 inhibits toll-like receptor-4 signaling in the intestinal epithelium. Gastroenterology 2010; 139: 904–917.e9176.

41.

Shanahan

Carroll

Grossniklaus

Mouse Paneth cell antimicrobial function is independent of Nod2. Gut 2014; 63: 903–910.

42.

Corridoni

Rodriguez-Palacios

Di Stefano

, et al. Genetic deletion of the bacterial sensor NOD2 improves murine Crohn’s disease-like ileitis independent of functional dysbiosis. Mucosal Immunol 2017; 10: 971–982.

43.

Sellin

Muller

Hardt

WD.

Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa. Cell Host Microbe 2014; 16: 237–248.

44.

Franchi

Kamada

Nunez

NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 2012; 13: 449–456.

45.

Steiner

Reygaerts

Masters

, et al. Recessive NLRC4-Autoinflammatory Disease Reveals an Ulcerative Colitis Locus. J Clin Immunol 2022; 42: 325–335.

46.

Williams

Leeth

Rothschild

, et al. The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis. J Immunol 2015; 194: 3369–3380.

47.

Wang

Chen

Yang

, et al. Secoisolariciresinol diglucoside suppresses Dextran sulfate sodium salt-induced colitis through inhibiting NLRP1 inflammasome. Int Immunopharmacol 2020; 78: 105931.

48.

Ranson

Veldhuis

Mitchell

NLRP3-Dependent and -Independent Processing of Interleukin (IL)-1β in Active Ulcerative Colitis. Int J Mol Sci 2018; 20: 57.

49.

Chen

Liu

Yuan

NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling. Cell Death Dis 2019; 10: 906.

50.

Yao

Zhang

Xing

, et al. Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis. Nat Commun 2017; 8: 1896.

51.

Kempster

Belteki

Forhead

AJ.

Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G253–G263.

52.

Yin

Sheng

Yang

The protective roles of NLRP6 in intestinal epithelial cells. Cell Prolif 2019; 52: e12555.

53.

Chen

Wilson

Koenigsknecht

, et al. NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol 2017; 18: 541–551.

54.

Kawamoto

Maruya

Kato

, et al. Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity 2014; 41: 152–165.

55.

Elias-Oliveira

Leite

Pereira

ÍS

, et al. NLR and intestinal dysbiosis-associated inflammatory illness: drivers or dampers? Front Immunol 2020; 11: 1810.

56.

Elinav

Strowig

Kau

, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745–757.

57.

Seregin

Golovchenko

Schaf

NLRP6 Protects Il10-/- Mice from Colitis by Limiting Colonization of Akkermansia muciniphila. Cell Rep 2017; 19: 733–745.

58.

Anand

Malireddi

Lukens

, et al. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Our Nat 2012; 488: 389–393.

59.

Hirota

Lueng

, et al. The NLRP3 inflammasome plays key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011; 17: 1359–1372.

60.

Bauer

Duewell

Mayer

, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192–1199.

61.

Liu

Zaki

Vogel

, et al. Role of inflammasomes in host defense against Citrobacter rodentium infection. J Biol Chem 2012; 287: 16955–16964.

62.

Yoganathan

Rossel

Jordi

SBU

, et al.; Swiss IBD cohort study group. Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterol 2021; 21: 310.

63.

Singh

Yeoh

Walker

, et al. Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation. Gut 2019; 68: 1801–1812.

64.

Bauer

Duewell

Lehr

, et al. Protective and aggravating effects of nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis 2012; 30 Suppl 1: 82–90.

65.

Biswas

Kobayashi

KS.

Regulation of intestinal microbiota by the NLR protein family. Int Immunol 2013; 25: 207–214.

66.

Sun

Jobin

890 defective NOD2-Induced bactericidal activity exacerbates Campylobacter Jejuni-Induced Colitis in Il10-/- mice. Gastroenterol 2013; 144: S–157.

67.

Couturier-Maillard

Secher

Rehman

, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Investig 2013; 123: 700–711.

68.

Zaki

Vogel

Malireddi

, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011; 20: 649–660.

69.

Frank

St Amand

Feldman

, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780–13785.

70.

Schubert

Rogers

Ring

, et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. Difficile-associated diarrhea from healthy controls. mBio 2014; 5: e01021–NaN14.

71.

Haberman

Tickle

Dexheimer

, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Investig 2014; 124: 3617–3633.

72.

Shen

Turner

JR.

Mechanisms and functional implications of intestinal barrier defects. Dig Dis 2009; 27: 443–449.

73.

Chelakkot

Ghim

Ryu

SH.

Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med 2018; 50: 1–9.

74.

Miyoshi

Takai

Structural and functional associations of apical junctions with cytoskeleton. Biochim et Biophys Acta 2008; 1778: 670–691.

75.

Pinton

Nougayrède

Del Rio

, et al. The food contaminant deoxynivalenol, decreases intestinal barrier permeability and reduces claudin expression. Toxicol Appl Pharmacol 2009; 237: 41–48.

76.

Nalle

Shen

, et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterol 2013; 145: 407–415.

77.

Al Nabhani

Montcuquet

Roy

, et al. Complementary roles of nod2 in hematopoietic and nonhematopoietic cells in preventing gut barrier dysfunction dependent on MLCK activity. Inflamm Bowel Dis 2017; 23: 1109–1119.

78.

Feng

Wang

, et al. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy. Cell Physiol Biochem 2018; 49: 190–205.

79.

Feng

Huang

Wang

, et al. Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. PLoS One 2019; 14: e0218384.

80.

Chen

Shi

, et al. 1,25-dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. Inflamm Bowel Dis 2015; 21: 2495–2506.

81.

Wlodarska

Thaiss

Nowarski

, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 2014; 156: 1045–1059.

82.

Normand

Delanoye-Crespin

Bressenot

, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108: 9601–9606.

83.

Zaki

Boyd

Vogel

, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immun 2010; 32: 379–391.

84.

Song-Zhao

Srinivasan

Pott

, et al. Nlrp3 activation in the intestinal epithelium protects against a mucosal pathogen. Mucosal Immunol 2014; 7: 763–774.

85.

Zhang

Liu

, et al. NLRC4 inflammasome-dependent cell death occurs by a complementary series of three death pathways and determines lethality in mice. Sci Adv 2021; 7: eabi9471.

86.

Cummings

Cooney

Clarke

, et al. The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens 2010; 76: 48–56.

87.

Jamontt

Petit

Clark

, et al. Nucleotide-binding oligomerization domain 2 signaling promotes hyperresponsive macrophages and colitis in IL-10-deficient mice. J Immunol 2013; 190: 2948–2958.

88.

Nayar

Morrison

Giri

, et al. A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn’s disease. Our Nat 2021; 593: 275–281

89.

Cui

Wang

Bai

CD1d1 intrinsic signaling in macrophages controls NLRP3 inflammasome expression during inflammation. Sci Adv 2020; 6: eaaz7290.

90.

Sugimoto

Ogawa

Mizoguchi

, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Investig 2008; 118: 534–544.

91.

Bishop

Roberts

Beer

, et al. Lyn activity protects mice from DSS colitis and regulates the production of IL-22 from innate lymphoid cells. Mucosal Immunol 2014; 7: 405–416.

92.

Chen

Liu

Wang

, et al. A functional role for nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011; 186: 7187–7194.

93.

Chavan

Pavlov

Tracey

KJ.

Mechanisms and therapeutic relevance of neuro-immune Communication. Immun 2017; 46: 927–942.

94.

Chaubey

Momin

Sawarkar

Significance of ligand-anchored polymers for drug targeting in the treatment of colonic disorders. Front Pharmacol 2019; 10: 1628.

95.

Ferrusquía

Pérez-Martínez

Gómez de la Torre

, et al. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol 2015; 21: 4069–4077.

96.

Leung

Lowery

The patent landscape of inflammasome modulators. Nat Rev Drug Discov 2020; 19: 158.

97.

Schwaid

Spencer

KB.

Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. J Med Chem 2021; 64: 101–122.

98.

Sun

Zhao

Yao

, et al. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation. Biochem Pharmacol 2015; 94: 142–154.

99.

Zhao

Guo

Zhu

, et al. Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress. Mucosal Immunol 2019; 12: 1150–1163.

100.

Gong

Zhao

Zhou

, et al. Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1β production. Mol Immunol 2018; 104: 11–19.

101.

Chen

You

, et al. The antioxidant procyanidin reduces reactive oxygen species signaling in macrophages and ameliorates experimental colitis in mice. Front Immunol 2017; 8: 1910.

102.

Cao

Liu

Shen

, et al. Protective Effect of naringin on DSS-Induced ulcerative colitis in mice. J Agric Food Chem 2018; 66: 13133–13140.

103.

Zhang

Cao

, et al. The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice. Food Funct 2019; 10: 422–431.

104.

Radulovic

Normand

Rehman

, et al. A dietary flavone confers communicable protection against colitis through NLRP6 signaling independently of inflammasome activation. Mucosal Immunol 2018; 11: 811–819.

105.

Wang

Miao

, et al. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. Biochem Pharmacol 2018; 155: 494–509.

106.

Wei

Wang

, et al. Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis. Sci Rep 2016; 6: 28370.

107.

Liu

Zhao

Bai

, et al. Formononetin protects against concanavalin-A-induced autoimmune hepatitis in mice through its anti-apoptotic and anti-inflammatory properties. Biochem Cell Biol 2021; 99: 231–240.

108.

Chen

, et al. Genistein protects against DSS-induced colitis by inhibiting NLRP3 inflammasome via TGR5-CAMP signaling. Int Immunopharmacol 2019; 71: 144–154.

109.

Luo

Wang

Huang

, et al. Paeoniflorin ameliorates experimental colitis by inhibiting gram-positive bacteria-dependent MDP-NOD2 pathway. Int Immunopharmacol 2021; 90: 107224.

110.

Fan

Chen

Zhu

, et al. Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/ho-1 signaling. Int Immunopharmacol 2019; 76: 105909.

111.

Guo

Liu

Jin

, et al. Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation. Int Immunopharmacol 2015; 24: 232–238.

112.

Liang

Chen

Fan

, et al. Dihydroartemisinin prevents dextran sodium sulphate-induced colitisthrough inhibition of the activation of NLRP3 inflammasome and p38 MAPK signaling. Int Immunopharmacol 2020; 88: 106949.

113.

Zhu

Wang

, et al. Ginsenoside Rg1 attenuates the inflammatory response in DSS-induced mice colitis. Int Immunopharmacol 2017; 50: 1–5.

114.

Saber

Abd El-Kader

Sharaf

, et al. Celastrol augments sensitivity of NLRP3 to CP-456773 by modulating HSP-90 and inducing autophagy in dextran sodium sulphate-induced colitis in rats. Toxicol Appl Pharmacol 2020; 400: 115075.

115.

Fan

Xiang

Chen

, et al. Libertellenone M, a diterpene derived from an endophytic fungus Phomopsis sp. S12, protects against DSS-induced colitis via inhibiting both nuclear translocation of NF-κB and NLRP3 inflammasome activation. Int Immunopharmacol 2020; 80: 106144.

116.

Tian

Zhang

, et al. Ginsenoside Rk3 alleviated DSS-induced ulcerative colitis by protecting colon barrier and inhibiting NLRP3 inflammasome pathway. Int Immunopharmacol 2020; 85: 106645.

117.

Mai

Wang

, et al. Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation. Mol Immunol 2019; 105: 76–85.

118.

Guo

Elgehama

, et al. Fumigaclavine C ameliorates dextran sulfate sodium-induced murine experimental colitis via NLRP3 inflammasome inhibition. J Pharmacol Sci 2015; 129: 101–106.

119.

Shen

Zhang

Zhu

, et al. Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation of NF-kappaB and NLRP3 inflammasome, Biomed Pharmacother 2019; 110:786-795.

120.

Chen

Wang

, et al. Therapeutic efficacy of carboxyamidotriazole on 2,4,6-trinitrobenzene sulfonic acid-induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF-κB activation. Int Immunopharmacol 2017; 45: 16–25.

121.

Wang

Qian

, et al. 3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one (compound 1), a novel potent Nrf2/are inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome. Biochem Pharmacol 2016; 101: 71–86.

122.

Zeng

Zhang

Wan

, et al. Chlorogenic acid suppresses miR-155 and ameliorates ulcerative colitis through the NF-κB/NLRP3 inflammasome pathway. Mol Nutr Food Res 2020; 64(23):e2000452.

123.

Lopes de Oliveira

Alarcón de la Lastra

Rosillo

MÁ

, et al. Preventive effect of bergenin against the development of TNBS-induced acute colitis in rats is associated with inflammatory mediators inhibition and NLRP3/ASC inflammasome signaling pathways. Chem Biol Interact 2019; 297: 25–33.

124.

Zhou

Wang

Dou

, et al. Brusatol ameliorates 2, 4, 6-trinitrobenzenesulfonic acid-induced experimental colitis in rats: involvement of NF-κB pathway and NLRP3 inflammasome. Int Immunopharmacol 2018; 64: 264–274.

125.

Huang

Kong

AN.

Anti-oxidative stress regulator NF-E2-related factor 2 mediates the adaptive induction of antioxidant and detoxifying enzymes by lipid peroxidation metabolite 4-hydroxynonenal. Cell Biosci 2012; 2: 1–7.

126.

Ouyang

Feng

, et al. Suppression of NF-κB signaling and NLRP3 inflammasome activation in macrophages is responsible for the amelioration of experimental murine colitis by the natural compound fraxinellone. Toxicol Appl Pharmacol 2014; 281: 146–156.

127.

Cao

, et al. 1,25(OH)2 D3 alleviates DSS-induced ulcerative colitis via inhibiting NLRP3 inflammasome activation. J Leukoc Biol 2020; 108: 283–295.

128.

Jiang

Zhong

Sun

, et al. Magnesium lithospermate B acts against dextran sodiumsulfate-induced ulcerative colitis by inhibiting activation of the NRLP3/ASC/Caspase-1 pathway. Environ Toxicol Pharmacol 2016; 41: 72–77.

129.

Zhang

, et al. Anti-colitic effects of physalin B on dextran sodium sulfate-induced BALB/c mice by suppressing multiple inflammatory signaling pathways. J Ethnopharmacol 2020; 259: 112956.

130.

Xia

Lin

Luo

, et al. Oryzanol ameliorates DSS-Stimulated gut barrier damage via targeting the gut Microbiota accompanied by the TLR4/NF-κB/NLRP3 cascade response in vivo. J Agric Food Chem 2022; 70: 15747–15762.

131.

, et al. Munronoid I ameliorates DSS-Induced mouse colitis by inhibiting NLRP3 inflammasome activation and pyroptosis via modulation of NLRP3. Front Immunol 2022; 13: 853194.

132.

Shao

Yan

Zhu

, et al. Artemisinin analog SM934 alleviates epithelial barrier dysfunction via inhibiting apoptosis and caspase-1-mediated pyroptosis in experimental colitis. Front Pharmacol 2022; 13: 849014.

133.

Gao

Fan

Tan

, et al. Soy isoflavones ameliorate experimental colitis by targeting ERα/NLRP3 inflammasome pathways. J Nutr Biochem 2020; 83: 108438.

134.

Zong

Zhang

, et al. Protective effect of Lachnum polysaccharide on dextran sulfate sodium-induced colitis in mice. Food Funct 2020; 11: 846–859.

135.

Sun

Pei

Guo

, et al. Gut microbiota-mediated NLRP12 expression drives the attenuation of dextran sulphate sodium-induced ulcerative colitis by Qingchang Wenzhong decoction. Evid Based Complement Alternat Med 2019; 2019: 1–12.

136.

Zhang

Kang

Sun

, et al. Qingre Jianpi decoction attenuates inflammatory responses by suppressing NOD-like receptor family pyrin domain-containing 3 inflammasome activation in dextran sulfate sodium-induced colitis mice. J Tradit Chin Med 2021; 41: 68–78.

137.

Tian

Liu

Yang

, et al. Astagalus polysaccharide attenuates murine colitis through inhibiton of the NLRP3 inflammasome. Planta Med 2017; 83: 70–77.

138.

Zong

Yang

Park

, et al. Dietary intake of Lycium ruthenicum Murray ethanol extract inhibits colonic inflammation in dextran sulfate sodium-induced murine experimental colitis. Food Funct 2020; 11: 2924–2937.

139.

Saba

Lee

Kim

, et al. A novel herbal formulation consisting of red ginseng extract and Epimedium koreanum Nakai-attenuated dextran sulfate sodium-induced colitis in mice. J Ginseng Res 2020; 44: 833–842.

140.

Mahmoud

El-Maadawy

Kandil

, et al. Canna x generalis L.H. Bailey rhizome extract ameliorates dextran sulfate sodium-induced colitis via modulating intestinal mucosal dysfunction, oxidative stress, inflammation, and TLR4/ NF-κs and NLRP3 inflammasome pathways. J Ethnopharmacol 2021; 269: 113670.

141.

Wang

, et al. Platycodon grandiflorum root fermentation broth reduces inflammation in a mouse IBD model through the AMPK/NF-κB/NLRP3 pathway. Food Funct 2022; 13: 3946–3956.

NOD-like receptors mediate homeostatic intestinal epithelial barrier function: promising therapeutic targets for inflammatory bowel disease

Abstract

Keywords

Introduction

Literature search strategy

The composition and function of the intestinal mucosal barrier

Biological barrier

Chemical barrier

Mechanical barrier

Immunological barrier

NLRs family and signaling mechanisms in the intestinal epithelial barrier

NOD-like receptors regulate homeostatic intestinal epithelial barrier function

Role of NLRs in modulating intestinal biologic barriers

Role of NLRs in modulating the intestinal mechanical barrier

Role of NLR in regulating mucosal immunity

Targeting NLRs with botanicals in IBD therapy

Flavonoids

Terpenoids

Alkaloids

Phenylpropanoids

Other compounds

Plant extracts

Conclusions and perspectives

Footnotes

Acknowledgements

Declarations

ORCID iD

References